Diffuse large B-cell lymphoma (DLBCL) is a hematological cancer associated with an aggressive clinical course. The predominant subtypes of DLBCL display features of chronic or tonic B-cell antigen receptor (BCR) signaling. However, it is not known whether the spatial organization of the BCR contributes to the regulation of pro-survival signaling pathways and cell growth. Here, we show that primary DLBCL tumors and patient-derived DLBCL cell lines contain high levels of phosphorylated Ezrin-Radixin-Moesin (ERM) proteins. The surface BCRs in both activated B cell and germinal B cell subtype DLBCL cells co-segregate with phosphoERM suggesting that the cytoskeletal network may support localized BCR signaling and contribute to pathogenesis. Indeed, ablation of membrane-cytoskeletal linkages by dominant-negative mutants, pharmacological inhibition and knockdown of ERM proteins disrupted cell surface BCR organization, inhibited proximal and distal BCR signaling, and reduced the growth of DLBCL cell lines. In vivo administration of the ezrin inhibitor retarded the growth of DLBCL tumor xenografts, concomitant with reduction in intratumor phosphoERM levels, dampened pro-survival signaling and induction of apoptosis. Our results reveal a novel ERM-based spatial mechanism that is coopted by DLBCL cells to sustain tumor cell growth and survival.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of all non-Hodgkin's lymphomas. 1 Gene expression profiling has revealed the existence of two germinal center (GC)-derived molecular subtypes of DLBCL, including GC B cell-like (GCB) and activated B cell-like (ABC). These subtypes differ in B-cell differentiation stage, oncogenic aberrations and responsiveness to standard therapy. [2] [3] [4] [5] [6] Patients with ABC-DLBCL have inferior response to conventional chemotherapy with the B-cell-depleting CD20 monoclonal antibody rituximab (that is, R-CHOP) and poorer overall survival. 7, 8 On the other hand, DLBCL patients with GCB subtype show an initial favorable response to R-CHOP but relapses are fatal, 7, 8 necessitating the development of alternate/combinatorial treatment strategies, and a better understanding of mechanisms involved in the pathobiology of DLBCL. ABC-DLBCL pathogenesis is associated with activating mutations in CD79A and CD79B, which leads to chronic B-cell antigen receptor (BCR) signaling, or in CARD11 or TAK1 proteins, causing constitutive activation of NF-κB and increased B-cell survival. [9] [10] [11] [12] GCB-DLBCLs exhibit activating mutations in Bcl2 and constitutive activation of the phosphatidylinositol 3-kinase (PI3K) pathway, which is a key element of tonic BCR signaling in B cells. 3 Targeting of critical activating enzymes in BCR signaling 10, [12] [13] [14] [15] has demonstrated that this pathway may be a viable therapeutic target in DLBCL. Thus, identification of novel regulators of B-cell activation in the GC should aid in expanding drug development efforts.
Ezrin-Radixin-Moesin (ERM) family proteins crosslink the plasma membrane and actin cytoskeleton, and facilitate several key cellular processes, including membrane dynamics, adhesion, cell survival, cell motility and morphogenesis. 16 An N-terminal fourpoint-one, ezrin, radixin, moesin (FERM) domain anchors ERMs in the plasma membrane through direct or indirect interaction with transmembrane proteins, and a C-terminal domain interacts with cortical actin filaments. In the inactive/dormant state, actin and membrane-binding sites are masked by intramolecular interaction between the N-and C-termini. 16 Functional activation of ERM proteins occurs upon phosphorylation of a conserved threonine residue at the C-terminus. 17, 18 Phosphorylated ezrin and actin filaments collaborate to form the structural core of surface microvilli 19, 20 where they can regulate diverse processes, including signal transduction. 21 We have previously shown that in naïve B cells, ezrin exists in an open/active conformation defined by basal phosphorylation at Thr567. Ezrin and actin physically collaborate to control the diffusion of the BCR in the absence of antigen. 22 BCR stimulation by antigen induces its transient dephosphorylation leading to uncoupling of the actin cytoskeleton from the plasma membrane. 23, 24 Simultaneously, B cells spread to gather antigen and the BCR organizes itself into microclusters and recruits key signaling proteins. [25] [26] [27] [28] Local rephosphorylation of ERM proteins reinstates the membrane-cytoskeletal barriers, trapping BCR microclusters within compartments and facilitating signal transduction. 29 Together, these features of ezrin enable it to regulate antigen-induced BCR signal transduction and humoral immunity. 30 Interestingly, ABC-DLBCL cells with mutations in the BCR exhibit spontaneous BCR microclustering, whereas in GCB-DLBCL cells, the BCR is present in surface microvilli. 9 In this study, we investigated the hypothesis that regulation of BCR organization by ERM proteins mediates DLBCL pathogenesis. We report that primary GCB cells, lymphoma biopsies from DLBCL patients and representative DLBCL cell lines contain high levels of ERM phosphorylation. Interference with ERM function decreases DLBCL cell growth and survival by disrupting BCR localization and impairing pro-survival signaling pathways. Therefore, we suggest that ERM proteins are novel molecular mediators of DLBCL pathogenesis whose activity may be targeted for intervention in the future.
MATERIALS AND METHODS

Human tissues
Frozen DLBCL patient tumor biopsy samples were obtained according to guidelines approved by the Institutional Review Board of the Cleveland Clinic. DLBCL patients were identified as GCB or ABC based on application of the Hans immunochemistry algorithm to fresh-frozen paraffinembedded tumor biopsies. 31 B cells were purified from PBMCs of healthy individuals using the human B cell isolation kit (Miltenyi Biotec Inc., San Diego, CA, USA). Tonsils were obtained from healthy individuals undergoing routine tonsillectomies in accordance with ethical recommendations. After mincing, tonsillar mononuclear cells were isolated by Ficoll density centrifugation (GE Healthcare, Pittsburgh, PA, USA). GCB cells were enriched by magnetic cell separation with anti-CD77, MARM-4 (Abcam, Cambridge, MA, USA) and IgG1 microbeads (Miltenyi Biotec Inc.).
Cell lines, transfection and knockdown
All DLBCL cell lines were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, except for OCI-LY-10 cells, which were grown in IMDM and 10% human serum. DLBCL cell lines were transiently transfected using the Lonza (Walkersville, MD, USA) nucleofector and nucleofection kit V. Briefly, three million cells and 3 μg DNA were resuspended in 100 μl solution V, and nucleofected using program A-020. The nucleofected cells were plated in 2 ml DLBCL growth medium until analyzed. The plasmid constructs used were wild-type ezrin in plasmid pEYFP (Ez-WT), 32 a truncation mutant of ezrin in plasmid pCB6 (Ez-DN, a.a. 1-310 containing the FERM domain but lacking the T567 phosphorylation site, 33 phosphomimetic mutant T567D in pEYFP (Ez-TD) 32 and a non-phosphorylatable mutant T567A in pEYFP (Ez-TA). For siRNA knockdown, pools of untagged Accell siRNAs against human ezrin, radixin, moesin and scrambled siRNAs were purchased from Dharmacon RNAi Technologies (Lafayette, CO, USA). Briefly, DLBCL cells (1.5 million/ml) were incubated with the Accell delivery medium containing 1-2 μM of siRNAs at 37°C according to the manufacturer's instructions (this procedure does not require electroporation). Following overnight incubation, 1 ml of fresh delivery medium was added to each well. Cells were counted every day up to 6 days using trypan blue to assess viability. Lysates collected at 96 h were analyzed by immunoblotting with antibodies to ERM proteins, pThrERM, actin, pAkt, Akt, pIκB and IκB.
Lysis and immunoblotting
DLBCL cell lines were either treated with dimethylsulfoxide (DMSO), NSC668394 (Calbiochem, Billerica, MA, USA), or NSC305787 (obtained from the National Cancer Institute), or transfected with different ezrin constructs, followed by lysis as described. 34 Freshly harvested tumor tissues from DMSO-and ezrin-inhibitor-treated mice were homogenized in lysis buffer 34 using a TissueRuptor (Qiagen, Valencia, CA, USA), and lysates were analyzed by immunoblotting.
Cell growth, apoptosis and flow cytometry assays DLBCL cell lines were either transfected with different mutant constructs of ezrin, or incubated with ezrin inhibitors, or siRNAs, or treated with the IκB kinase (IKK) inhibitor PS-1145 (Sigma-Aldrich, St Louis, MO, USA) and viable cell counts were obtained using trypan blue staining. For tumor cell apoptosis assay, single-cell suspensions were obtained by placing tumors in 1 ml dissociation buffer (100 U/ml collagenase type I and 100 μg/ml DNase in RPMI+10% FBS) and incubating at 37°C for 30 min. Cell suspensions were passed through a 40 μ strainer to harvest mononuclear cells, and stained with Annexin V-phycoerythrin conjugate. Surface BCR levels were analyzed by fixing the DLBCL cells with 4% paraformaldehyde and labeling IgM or IgG with Rhodamine Red-X-conjugated goat anti-human IgM (μ chain-specific) Fab fragment or AlexaFluor 488-conjugated goat anti-human IgG (H+L specific) Fab fragment (Jackson Immunoresearch, West Grove, PA, USA) for 30 min at 4°C. The cells were subjected to flow cytometry on a BD FACSCalibur (San Jose, CA, USA) and data analyzed using FlowJo software (Treestar, Inc., Ashland, OR, USA).
Mouse xenograft assay
Ten million OCI-LY-10 or SU-DHL-6 cells were suspended in PBS and injected subcutaneously into the flanks of 6-week-old female NSG mice. After the tumor size reached~200 mm 3 , half the mice were injected intraperitoneally with 5% DMSO and the other half with 13.5 mg/kg/day of NSC668394. Tumor volume was determined by digital calipering three times a week and calculated using the formula (smallest diameter 2 × largest diameter)/2. Mice were periodically weighed and observed for discomfort and grooming behavior. Animal studies were conducted in accordance with guidelines approved by the Cleveland Clinic Institutional Animal Care and Use Committee.
Immunocytochemistry DLBCL cells were fixed in 10% buffered formalin overnight. After washing with PBS, the cells were mixed with HistoGel (Richard-Allan Scientific, Waltham, MA, USA), placed in cellblock cassettes, processed overnight using conventional histological techniques and embedded in paraffin. Immunocytochemistry was performed using an automated immunostainer (Discovery Ultra, Ventana Medical Systems, Tucson, AZ, USA). After deparaffinization and heat-induced epitope retrieval, slides were incubated with pThrERM antibody and OmniMap anti-rabbit HRP (Ventana Medical Systems, Inc., Tucson, AZ, USA). Staining was developed using ChromoMap DAB kit (Ventana), and the cells counterstained with hematoxylin. The sections were dehydrated and mounted in Cytoseal XYL (Richard-Allan Scientific), and the slides viewed using a digital light microscope (Olympus, Center Valley, PA, USA) with a × 10 objective.
Total internal reflection fluorescence microscopy DLBCL cells were left untreated, or transfected with Ez-DN or incubated with Ez-Inh, following by fixation in 4% paraformaldehyde. For colocalization analysis of BCR and tyrosine phosphorylated proteins, the former were labeled with Rhodamine Red-X-conjugated goat anti-human IgM or IgG Fab fragment (Invitrogen, Grand Island, NY, USA) for 30 min at 4°C, followed by staining with a fluorescein isothiocyanate-conjugated mouse monoclonal antibody to pY (clone 4G10; EMD Millipore, Billerica, MA, USA). For co-localization analysis of BCR and phosphorylated ERM proteins, the former were labeled with AlexaFluor 488-conjugated goat anti-human IgM or IgG Fab fragment (Invitrogen) for 30 min at 4°C, followed by fixation and staining with a rabbit polyclonal pThrERM antibody (Cell Signaling, Danvers, MA, USA) and a rhodamine-conjugated goat anti-rabbit IgG antibody (Jackson Immunoresearch). The cells were imaged at the depth of 130-150 nm using a Leica-AM total internal reflection fluorescence microscope DMI6000 (Leica Microsystems, Buffalo Grove, IL, USA) with an attached Hamamatsu (Buffalo Grove, IL, USA) EM-CCD camera and Leica acquisition software LAS AF Version 2.2.0. An HCX PL APO × 100 oil objective (NA = 1.47) was used at an additional × 1.6 magnification with appropriate filter cubes. The images were digitally deconvolved using the 'iterative restoration' function, and analyzed for BCR cluster number and area, and microvilli number and length in Volocity 6.0. For co-localization analysis, the deconvolved images were thresholded and Pearson's correlation coefficients calculated using Volocity 6.0.
Statistical Analysis
Statistical analysis was performed using Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA), and significance determined by employing Student t test. P value ofo0.05 was considered significant.
RESULTS
Interference with ERM function inhibits DLBCL growth
To examine whether ERM proteins were phosphorylated at the C-terminal conserved threonine residue in DLBCL tumors and cell lines, we used an antibody to pThrERM, which binds to phosphorylated ezrin, moesin and radixin. Lysates prepared from lymphoma biopsy tissues from 12 ABC-and 13 GCB-DLBCL patients showed heterogeneous but high pThrERM levels ( Figure 1a ). Immunohistochemical analysis of four of the representative DLBCL cell lines OCI-LY-10, OCI-LY-3, TMD8 and SU-DHL-6 showed punctate pThrERM staining at the cell periphery ( Figure 1b and zoomed-in panels). To test whether high ERM phosphorylation in DLBCL tissues and cell lines was tumor-specific, we purified circulating B cells from blood and GCB cells from tonsils of three healthy individuals and compared their pThrERM levels. ERM phosphorylation was barely detectable in healthy peripheral B cells but primary GCB cells contained high pThrERM levels (Supplementary Figure 1a ).
As phosphorylated ezrin regulates tumor cell growth and metastasis in several epithelial cell-derived cancers, we tested whether interfering with the function of ERM proteins would affect the growth of DLBCL cells. ERM proteins do not possess intrinsic enzymatic activity; therefore, targeting their function has relied largely on ectopic expression of dominant-negative mutants of ezrin or moesin, which contain the FERM domain but lack the conserved threonine phosphorylation site and thus compete with endogenous ERM proteins for binding to transmembrane proteins. This results in the removal of endogenous ERM proteins from the cell surface and threonine dephosphorylation. [35] [36] [37] We used the dominant-negative mutant of ezrin (Ez-DN; Supplementary Figure  1b Figure 1b) . Lysates of OCI-LY-10 transfectants showed comparable expression of Ez-WT, Ez-TD and Ez-TA ( Supplementary Figure 1d ). As the Ez-DN construct is not fluorescently tagged, we used the Ez-WT-YFP construct as a reporter of transfection efficiency by flow cytometry. Data in Supplementary Figure 1e show that 61.9% of OCI-LY-10, 68.2% of OCI-LY-3 and 74.2% of SU-DHL-6 cells express Ez-WT-YFP. Interestingly, Ez-WT boosted cell growth 72 h onwards, whereas despite its constitutive activation Ez-TD did not have an appreciable effect on cell growth ( Supplementary Figure 1f ). Ez-TA, which also acts as a dominant-negative mutant like Ez-DN, resulted in the progressive loss of cell viability ( Supplementary  Figure 1f ).
Pharmacological inhibition of ERM phosphorylation impairs DLBCL cell growth
As an alternate strategy to inhibit ERM function, we used novel compounds (NSC668394, NSC305787) identified in a recent small molecule screen in osteosarcoma cells that directly bind to ezrin, and abrogate its phosphorylation. 38 To test the efficacy of these compounds on DLBCL growth, we treated OCI-LY-10 cells with varying doses of NSC305787 or NSC668394 for 1 h. Both compounds led to the dephosphorylation of all three ERM proteins ( Supplementary Figures 2a and b ), and impaired cell growth ( Supplementary Figures 2c and d ) in a dose-and time-dependent manner. As the IC 50 value for inhibition of cell growth by NSC668394 (5.8 μM) was slightly lower than that for NSC305787 (8.7 μM), we performed all subsequent inhibition experiments with NSC668394. DLBCL cell lines OCI-LY-10, SU-DHL-6 and OCI-LY-3 were treated with increasing concentrations of NSC668394 for 1 h, and dose-dependent dephosphorylation of the three ERM proteins was observed in all cell lines, albeit the effect was the strongest in OCI-LY-10 and weakest in OCI-LY-3 cells (Figure 3a ). NSC668394 treatment led to a dose-dependent decrease in the growth of CD79 mutant ABC-DLBCL cell lines OCI-LY-10, TMD8 and HBL1, and the GCB-DLBCL cell lines SU-DHL-6 and SU-DHL-4, but not the CARD11 mutant OCI-LY-3 cell line (Figure 3b ). As reported previously, 39 the growth of OCI-LY-3 cells was inhibited upon treatment with the IKK inhibitor PS-1145 ( Supplementary Figure 3 ). Induction of apoptosis was observed in OCI-LY-10, TMD8, HBL1 and SU-DHL-6 but not OCI-LY-3 cells (Figure 3c ). To ensure that NSC668394 specifically targets ERM proteins, a rescue experiment was performed in which we transiently transfected OCI-LY-10 and SU-DHL-6 cells with pEYFP vector or Ez-WT, followed by treatment with 5 μM of NSC668394 for 5 days. Expression of Ez-WT overcame the decrease in viability of OCI-LY-10 ( Figure 3d ) and SU-DHL-6 ( Figure 3e ) cells in the presence of NSC668394 by greater than 60%. To further confirm that ERM proteins contribute to DLBCL cell growth, we knocked down their expression using siRNAs (siERM) in OCI-LY-10 and SU-DHL-6 cells. The expression and phosphorylation of ERM proteins was decreased by 480% in cells treated with siERM as compared with those treated with scrambled siRNAs (siControl) after 96 h (Supplementary Figure  4a) . ERM knockdown did not affect the expression of actin ( Supplementary Figure 4a ). ERM knockdown also led to a timedependent decrease in the growth of OCI-LY-10 and SU-DHL-6 cells ( Supplementary Figure 4b) .
ERM proteins are co-localized with the BCRs in DLBCL It is well established that dynamic phosphorylationdephosphorylation of ERM proteins regulates the formation and maintenance of membrane microvilli and ruffles, as well as BCR clustering in antigen-stimulated mouse B cells. 21, 22, 29, 30, 32 Therefore, we examined the spatial relationship of the BCR in DLBCL cells with phosphorylated ERM proteins by total internal reflection fluorescence microscopy at a depth of 130-150 nm, a region that encompasses the plasma membrane and cell cortex. The CD79 mutant ABC-DLBCL cell lines (OCI-LY-10, TMD8 and HBL1) exhibited BCR arrangement in spontaneous clusters as previously reported 9 (Supplementary Figure 5a) . The CARD11 mutant OCI-LY-3 cell line also showed surface BCR clusters, but these were much smaller ( Supplementary Figure 5a) . The GCB-DLBCL cell lines (SU-DHL-4 and SU-DHL-6) showed a streaky BCR distribution ( Supplementary Figure 5b) , reminiscent of membrane microvilli. 9, 32 The BCRs showed co-segregation with threoninephosphorylated ERM proteins in OCI-LY-10 cells (Figure 4a ), OCI-LY-3 ( Figure 4b ) and SU-DHL-6 ( Figure 4c ) cells. Quantification by Pearson's correlation analysis showed that the co-localization of the BCR with pThrERM was similar in OCI-LY-10 and SU-DHL-6 cells, but weaker in OCI-LY-3 cells (Figure 4d ).
ERM inhibition abrogates BCR clustering and localization in microvilli
To investigate whether ERM inhibition would affect BCR localization and distribution in DLBCL cells, we either transfected OCI-LY-10, OCI-LY-3 and SU-DHL-6 cells with Ez-DN or treated them with 5 μM of NSC668394. Mock-transfected OCI-LY-10 cells showed large BCR clusters ranging from 2 to 12 per cell with an average of 5 clusters per cell. Ez-DN-transfected cells showed a 50% reduction in the number of large clusters (Figure 5a ), as well as a decrease in the area of the BCR clusters from 5 to 3 μm 2 (Figure 5a ). Treatment of OCI-LY-10 cells with NSC668394 led to a similar decrease in the number and size of spontaneous BCR clusters as compared with DMSO-treated cells (Figure 5b) . Expression of wild-type ezrin (Ez-WT) in OCI-LY-10 cells treated with 5 μM of Ez-Inh restored surface BCR clusters ( Supplementary  Figures 6a and b) . Although the number of BCR clusters in OCI-LY-3 cells was similar to that in OCI-LY-10 cells, the area of these clusters was only~1 μm 2 (Figures 5c and d) . Both the number and size of BCR clusters in OCI-LY-3 cells was significantly reduced in the presence of Ez-DN ( Figure 5c ) and NSC668394 (Figure 5d ). As the streaky BCR distribution in GCB-DLBCL cell lines resembled that of the microvillar ezrin localization reported by us in murine IgG + B lymphoma cell line 2PK3, 32 we quantified the length and number of the BCR-rich microvilli in the absence and presence of Ez-DN or NSC668394. SU-DHL-6 cells showed numerous BCR streaks, whose length ranged from 1 to 5 μm. Both, expression of Ez-DN ( Figure 5e ) and treatment with NSC668394 ( Figure 5f ) caused a significant reduction in the number and length of BCRcontaining microvilli. Inhibition of ERM proteins by NSC668394 (left panels) or Ez-DN (right panels) did not alter the overall surface IgM expression in OCI-LY-10 ( Supplementary Figure 6c) or OCI-LY-3 ( Supplementary Figure 6d Figure 6e ).
Inhibition of ERM function impairs proximal and distal signaling
As alterations in cell surface distribution of the BCRs regulates protein tyrosine phosphorylation and downstream activation signals in antigen-stimulated B cells, 29, 30 we imaged the spatial interaction of surface BCRs with tyrosine phosphorylated (pY) proteins in DLBCL cells. The BCRs co-localized with pY-containing proteins in OCI-LY-10 ( Figure 6a ) and SU-DHL-6 ( Figure 6b ) cells but not in OCI-LY-3 cells (Figure 6c ). The extent of co-localization between BCR and pY was higher in SU-DHL-6 cells than OCI-LY-10 cells, and it was the weakest in OCI-LY-3 cells (Figure 6d ). Next, we tested whether disruption of surface BCR organization by ERM inhibition would affect proximal BCR signaling. For this, OCI-LY-3, Figure 6f, lane 0) . Expression of Ez-DN (Figure 6e ) or treatment with NSC668394 (Figure 6f ) led to the reduction in tyrosine phosphorylation in both OCI-LY-10 and SU-DHL-6 cells but the effect was minimal in OCI-LY-3 cells (Figures 6e and f) . We further examined the effect of ERM inhibition on components of downstream NF-κB and PI3K activation, which are constitutively turned on in ABC-DLBCL and GCB-DLBCL. 10, 40 Expression of Ez-DN resulted in a marked reduction in the phosphorylation of IκBα and Akt in OCI-LY-10 but not OCI-LY-3 cells (Figure 6g ). SU-DHL-6 cells expressing Ez-DN showed reduced pAkt levels but no effect on pIκBα (Figure 6g ). Expression of anti-apoptotic proteins Bcl2, Bcl XL and Mcl1 was significantly reduced in both OCI-LY-10 and SU-DHL-6 but not in OCI-LY-3 cells (Figure 6g ). Like Ez-DN, NSC668394 also inhibited the Figure 7b ) also reduced the phosphorylation of IκB and Akt in TMD8 cells, but only that of Akt in SU-DHL-4 cells. NSC668394induced reduction in tyrosine phosphorylation ( Supplementary  Figure 7c ), impairment of NF-κB and PI3K signaling and Bcl2 expression ( Supplementary Figure 7d) were all reversed by overexpression of Ez-WT. This effect could already be observed at 48 h of Ez-WT expression, but was maximal at 120 h ( Supplementary Figures 7c and d) . Furthermore, siRNA-induced knockdown of ERM expression reduced PI3K and NF-κB activation in OCI-LY-10, and only PI3K activation in SU-DHL-6 cells ( Supplementary Figure 7e ).
Inhibition of ERM function in vivo retards the growth of DLBCL xenografts
Next, we investigated the effect of ERM inhibition on lymphoma growth in vivo. For this, we used DLBCL cell line transplantation into NOD-SCID-γ -/-(NSG) mice, which lack B, T and natural killer cells and cannot reject human lymphoma cell xenografts. We generated 12 OCI-LY-10 and 20 SU-DHL-6 tumor xenografts by injecting both flanks of 6 and 10 NSG mice, respectively. After the tumor volume reached~200 mm 3 , half of the mice in each cell line group received 5% DMSO and the other half received 13.5 mg/kg/day NSC668394. The growth of SU-DHL-6 xenografts was more robust than OCI-LY-10 xenografts (Figures 7a and b) , and reached IACUC-approved limit for euthanasia sooner, thus limiting the duration of NSC668394 treatment to 9 days in SU-DHL-6 tumor-bearing mice. NSC668394-treated mice showed significant reduction in the growth of both OCI-LY-10 ( Figure 7a ) and SU-DHL-6 ( Figure 7b ) xenografts as compared with those treated with DMSO. The mice tolerated the inhibitor well with no evidence of toxicity in terms of grooming behavior or weight loss (Supplementary Tables S1 and S2). Tumor cells from OCI-LY-10 ( Figure 7c ) and SU-DHL-6 ( Figure 7d ) xenografts harvested from NSC668394-treated mice exhibited a marked increase in the proportion of Annexin V + apoptotic cells as compared with those from DMSO-treated mice. Furthermore, tumor tissue lysates showed that NSC668394 treatment reduced the pThrERM levels in both OCI-LY-10 ( Figure 7e ) and SU-DHL-6 ( Figure 7f ) xenografts as compared with DMSO treatment, demonstrating in vivo activity of the inhibitor towards ERM proteins. Reduced pThrERM levels were accompanied by reduction in levels of pIκB, pAkt, Bcl2 and Mcl1 in OCI-LY-10 xenografts (Figure 7e ), and pAkt, Bcl2 and Mcl1 levels in SU-DHL-6 xenografts (Figure 7f ).
Taken together, our data demonstrate that phosphorylated ERM proteins constitute an important pathogenic axis that promotes growth and survival of DLBCLs.
DISCUSSION
In this study, we demonstrate that ERM proteins are key participants in DLBCL pathogenesis. We show that ERM proteins interact with spontaneously occurring cell surface BCR assemblies in the ABC and GCB subtypes of DLBCL. Abrogation of ERM function results in the loss of BCR organization, blocks transmission of proximal BCR signals to NF-κB and PI3K pathways and retards DLBCL growth in vivo. As BCR organization is an important upstream step in the nucleation of B-cell growth, 27, [41] [42] [43] our data underscore the importance of spatially organized signaling in DLBCL cells, and suggest that pathogenic DLBCL cells co-opt the 'normal' function of ERM proteins to promote their own growth and survival. Our findings further suggest that blocking ERM function may represent a novel strategy for controlling the growth of DLBCL tumors.
Cell lines representing the different subtypes of DLBCL demonstrated a graded response to ERM inhibition in our study; the GCB and CD79 mutant ABC-DLBCL cells showed similar sensitivity, whereas the CARD11 mutant ABC-DLBCL cells were largely insensitive. We observed that instead of organizing into microclusters, the BCRs in GCB-DLBCL are localized in membrane microvilli, consistent with previous studies, 9 and the observation that mouse and human GC B cells bear dendritic structures during T-cell-dependent immune response. 44 The decrease in the number and length of microvilli upon ERM inhibition suggests that these membrane structures are supported by ERM proteins, which is in agreement with their known function. 21, 45 The coincident reduction in surface BCR expression upon ERM inhibition in GCB-DLBCL suggests that the BCRs may be internalized upon microvillar resorption, and that this at least partially contributes toward quantitative reduction in the cell surface signaling apparatus. On the other hand, ERM inhibition did not affect the surface BCR expression but resulted in smaller BCR clusters in ABC-DLBCL cell lines, suggesting that BCR single molecules or nanoclusters may be released from ERM networkbased corrals. These smaller-sized BCR assemblies are not detectable by the resolution of total internal reflection fluorescence imaging used in this study, but may be more readily visualized by super resolution imaging modalities such as photoactivated localization microscopy 46, 47 or stochastic optical reconstruction microscopy. 30, 48, 49 In the CD79 mutant ABC-DLBCL, de-clustering of the BCRs was associated with decreased prosurvival signaling with impairment of cell growth. The CARD11 mutant ABC-DLBCL cell line OCI-LY-3 showed much lower basal tyrosine phosphorylation than OCI-LY-10 cells, and their BCRs were not co-localized with tyrosine-phosphorylated proteins, supporting the notion that proximal BCR signaling is not a remarkable feature of this mutant subtype. 12 OCI-LY-3 cells were killed upon inhibition of IKK, an enzyme that functions downstream of CARD11 in the NF-κB activation pathway, 50 further emphasizing the importance of NF-κB signaling as the main pathogenic mechanism in CARD11 mutant DLBCL cells. 39 Our data also indicate that ERM proteins promote DLBCL growth by acting upstream of CARD11, and that agents altering BCR organization may not be effective in patients whose lymphomas bear mutations in NF-κB signaling proteins.
A role for both chronic active BCR signaling and tonic BCR signaling in maintaining lymphoma survival has been appreciated in recent years. 10, 51, 52 Chronic active signaling was described for ABC-DLBCL with gain-of-function mutations in Igα and Igβ, whose sustained signaling at the surface maintains NF-κB activation. On the other hand, tonic signaling is largely associated with the surface BCR and PI3K pathway. 51, 52 Here, we use the term 'pathogenic BCR signaling', which is conventionally associated with the ABC subtype of DLBCL, to also encompass the GCB subtype because of the following evidence. The BCRs co-localize with tyrosine-phosphorylated proteins in membrane microvilli in GCB-DLBCL, and lysates of these cells contain several prominent tyrosine-phosphorylated protein bands. These data indicate BCRassociated basal tyrosine kinase activity in GCB-DLBCL, which may represent tonic signaling. ERM inhibition causes reduction in surface BCR levels in GCB-DLBCL (because of resorption of microvilli), and concomitant inhibition of PI3K signaling. As these effects of ERM inhibition are associated with loss of cell and tumor growth, we suggest that ERM-mediated subcellular BCR organization mediates 'pathogenic' BCR signaling in the GCB subtype. Overall, our data suggest that ERM-mediated subcellular BCR organization in microclusters or microvilli supports pathogenic BCR signaling and DLBCL growth (Figure 8 ). PI3K is not only a component of GCB survival, but also a critical feature of tonic BCR signaling, as it can rescue mature B-cell survival in the absence of the BCR. 53 The p110δ catalytic subunit of PI3K is recruited to Igα and Igβ via the small Ras family GTPase TC21. 53, 54 Alternatively, PI3K can be included within the BCR complex through direct binding to CD19, a co-receptor that is known to promote BCR signaling. 49, 55, 56 As ERM inhibition disrupts BCR assembly in the microvilli in GCB-DLBCL cells, associated with loss of tyrosine phosphorylation, PI3K signaling and cell growth, we propose that ERM proteins may support tonic BCR signaling in microvilli in GCB-DLBCL by enabling BCR-CD19/TC21-PI3K assembly.
Phosphorylation at the conserved threonine site in the C-terminal F-actin-binding domain is believed to be a necessary step in the conformational activation of ERM proteins, 18 and also responsible for the functional redundancy between them. 45 The two non-phosphorylatable mutants Ez-DN and Ez-TA interfered with DLBCL growth but the constitutively active mutant Ez-TD, which is irreversibly trapped in the open conformation, did not. On the other hand, overexpression of Ez-WT significantly enhanced the growth of OCI-LY-10 cells, suggesting that dynamic and reversible regulation of ERM phosphorylation is necessary for supporting cell growth in DLBCL. We have previously reported that genetic deletion of ezrin amplifies BCR signaling in naïve mouse B cells, 30 whereas in this study, interfering with ERM function disrupted BCR signaling in DLBCL cell lines. The data obtained in DLBCL cell lines are in agreement with those of Treanor et al. 29 who reported that expression of dominantnegative mutants of ezrin or knocking down expression of ezrin and moesin disrupts the integrity of BCR clusters and reduces the strength of BCR signaling in mouse lymphoma B-cell lines. 29 The opposite effects of ERM inhibition in naïve and lymphoma B cells suggest that the impact of the cytoskeletal network on B-cell activation is context-dependent. The differences may stem from the type of stimulation experienced by naïve and GC-origin B cells. Naïve B cells respond to BCR crosslinking acutely by dephosphorylating ERM proteins, and rephosphorylating them upon continuous stimulation. On the other hand, continual survey of antigens in the GC by the BCR is a property of GC B cells and must be necessary for selection and survival. 57, 58 We observed that like DLBCL patient tissue and cell lines, primary GC B cells also contain high levels of phosphorylated ERM proteins. It is possible that high pThrERM levels in GC B cells serve to tether/corral BCRs at the cell surface for efficient antigen recognition, selection and differentiation. In DLBCL cells, a 'self antigen' may drive continuous stimulation of the BCRs and aid in lymphoma cell survival. 51, 59 Thus, DLBCLs likely represent transformed GC B cells that are undergoing chronic active or tonic BCR signaling supported by the ERM network. The outcome of ERM inhibition in naïve mouse B cells and GC-derived lymphomas may be additionally influenced by other microenvironmental stimuli. Indeed, a detailed investigation of the role for the cytoskeletal network in primary naïve versus GC B cells is warranted, and should provide mechanistic insights into spatial and molecular control of stage-specific B-cell activation, selection and differentiation.
Hyperphosphorylation of ezrin is frequently associated with growth, metastasis and poor prognosis in a variety of clinically aggressive human cancers, including hepatocellular carcinoma, breast cancer and osteosarcomas. 35, 60, 61 Knockdown of ezrin expression abrogates invasion, early metastatic survival as well as lung metastases in osteosarcoma 35 and breast carcinoma. 36 Likewise, our data support an important role for phosphorylated ERM proteins in promoting DLBCL cell survival, albeit through regulation of BCR organization. As ERM proteins also facilitate communication between cells and their microenvironment, and response to chemokines and cytokines, 32, 62 it will be interesting to explore additional roles for ERM proteins in DLBCL cell dissemination and interaction with the tumor microenvironment. Finally, a variety of novel kinase inhibitors have been developed to target various proteins associated with lymphoma cell survival, including Syk, PI3K, Btk and PKCβ and JAK2/STAT3. 10, 14, 15, [63] [64] [65] Combining ERM inhibitors with these and other novel therapies may suppress multiple critical cell survival pathways simultaneously and offer therapeutic synergy.
